{"id":"NCT02795767","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors","officialTitle":"A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-22","primaryCompletion":"2018-04-30","completion":"2020-11-11","firstPosted":"2016-06-10","resultsPosted":"2019-04-10","lastUpdate":"2021-06-02"},"enrollment":88,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"DRUG","name":"Emicizumab","otherNames":["Hemlibra","RO5534262","RG6013","ACE910"]}],"arms":[{"label":"Cohort A: 1.5 mg/kg Emicizumab QW","type":"EXPERIMENTAL"},{"label":"Cohort B: 3 mg/kg Emicizumab Q2W","type":"EXPERIMENTAL"},{"label":"Cohort C: 6 mg/kg Emicizumab Q4W","type":"EXPERIMENTAL"}],"summary":"This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.","primaryOutcome":{"measure":"Cohort A: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Treated Participants <12 Years of Age","timeFrame":"From Baseline to 52 weeks; At the primary completion date, the median (min-max) duration of the efficacy period in Cohort A was 57.57 (17.9-92.6) weeks.","effectByArm":[{"arm":"Cohort A: 1.5 mg/kg Emicizumab QW","deltaMin":0.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":28,"countries":["United States","Costa Rica","France","Germany","Italy","Japan","South Africa","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35939785","31697801"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":68},"commonTop":["Nasopharyngitis","Pyrexia","Injection site reaction","Upper respiratory tract infection","Cough"]}}